

ADS/BSE/2023-24/05/02

Dated 14/02/2024

To,
The General Manager Listing Department
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street Mumbai, Maharashtra

Sub: Compliance as per regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulation, 2015.

Company Code -523031

Dear Sir,

Please find herewith a copy of the approved unaudited financial results of the company and limited review report issued by M/s. V.N. Purohit & Co. Chartered Accountants and Statutory Auditors of the company for the quarter ended 31st December, 2023 approved in its meeting of the board of directors dated 14th February, 2024.

The Board Meeting commenced at 11:30 a.m. and concluded at 12:40 p.m.

Please take the same on record.

Thanking You.

Yours Faithfully

For ADS Diagnostic Limited



N.L. Gayari
Chief Financial Officer
& Company Secretary.

Encl.:- A/a



A D S DIAGNOSTIC LIMITED
Regd. Office: 114 Sant Nagar, East of Kailash, New Delhi 110065

www.adsdiagnosticltd.com, E-mail: -adsmedical@rediffmail.com

CIN NO. L85110DL1984PLC018486

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2023



Rs. In Lacs except Shares and EPS

Particulars	Quarter Ended			Nine Months Ended		Previous Accounting Year Ended 31.03.2023
	31.12.2023	31.12.2022	30.09.2023	31.12.2023	31.12.2022	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from Operations						
a) Revenue from Operations (Net)	710.47	367.25	772.29	1,805.21	797.90	1329.48
b) Other Operating Income	2.47	8.56	0.15	6.02	41.99	51.39
Total Income (a+b)	712.95	375.81	772.44	1,811.24	839.89	1,380.88
2 Expenses						
a) Cost of materials Consumed	449.82	212.86	408.35	984.45	347.53	673.67
b) Employee benefits expense	65.04	64.35	62.04	185.17	180.00	231.79
c) Depreciation and amortisation expense	4.08	4.22	4.14	12.40	14.98	19.12
d) Finance costs	15.97	5.58	18.52	41.53	30.19	43.91
e) Other expenses	118.00	65.02	143.66	387.29	222.05	274.73
Total expenses (a+b+c+d+e)	652.90	352.03	636.71	1,610.83	794.75	1,243.23
3 Profit / (loss) before Tax and exceptional item (1-2)	60.04	23.78	135.73	200.40	45.14	137.65
3(a) Exceptional Item	-	-	-	-	-	89.01
4 Profit / (loss) before Tax	60.04	23.78	135.73	200.40	45.14	48.64
5 Tax expenses						
Current Income Tax	15.11	6.94	34.16	50.44	11.36	14.02
Income Tax - Earlier Years						
Deferred tax charge	2.73		(3.95)	(1.85)		(5.98)
Total Tax Expenses (a+b+c)	17.84	6.94	30.21	48.59	11.36	8.04
6 Net Profit & Loss after Tax for the period (4-5)	42.21	16.84	105.51	151.82	33.78	40.60
7 Other Comprehensive Income, Net on Income Tax						
a) i) Items that will not be reclassified to profit or loss						5.12
ii) Income tax relating to items that will not be reclassified to profit or loss						(1.29)
b) i) Items that will be reclassified to profit or loss						
ii) Income tax relating to items that will be reclassified to profit or loss						
Total other comprehensive income, net of income tax						3.83
8 Total other comprehensive income after tax (6+7)	42.21	16.84	105.51	151.82	33.78	44.43
9 Paid-up Equity Share Capital (Face Value of Rs 10/- each)	219.28	219.28	219.28	219.28	219.28	219.28
10 Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	212.55	185.42	212.55	212.55	185.42	185.42
11 Earnings Per Share (EPS) (Rs.)						
a) Basic EPS	1.92	0.77	4.81	6.92	1.54	1.85
b) Diluted EPS	1.92	0.77	4.81	6.92	1.54	1.85

Notes

- The above Unaudited Financial Results were reviewed by the Audit Committee and approved by Board of Directors at their respective meetings held on 14.02.2024 and the statutory auditors have carried out a limited review of the said unaudited financial results.
- The Company is engaged in the business of "Trading of diagnostic medical consumables & electronic consumables, servicing of medical equipments & machines" and, therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segments".
- Figures for the previous period have been recast / regrouped / rearranged, wherever necessary, to conform to the current period's classification.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Amendment Rules, 2016 prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and relevant amendment rules thereafter.

For A D S DIAGNOSTIC LIMITED

Dr. Gautam Sehgal
Managing Director
DIN 0003243

Place : New Delhi
Date : 14th Feb 2024

ADS DIAGNOSTIC LIMITED

114, SANT NAGAR, EAST OF KAILASH, NEW DELHI -110065

TEL. : 011-41622193, 41620434, FAX.: 011-41665880, ☎ : 07290037529, E-mail : adsmedical@redi-mail.com

CIN:- L85110DL1984PLC018486, Udyam Registration Number (MSME) - UDYAM-DL-08-0007361



V. N. PUROHIT & CO.

CHARTERED ACCOUNTANTS

214, New Delhi House, 2nd Floor,
27, Barakhamba Road,
New Delhi – 110 001
Phone : 011-43596011
Email: delhi@vnp.in
Website: <http://www.vnp.in>

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM UNAUDITED FINANCIAL RESULTS

To Board of Directors of
A D S Diagnostic Limited
114, Sant Nagar, East of Kailash,
New Delhi - 110065
(CIN: L85110DL1984PLC018486)

We have reviewed the accompanying statement of unaudited financial results of **M/s. A D S Diagnostic Limited** (the "Company") for the quarter and nine months ended on 31st December, 2023 (the "Statement") being submitted by the Company pursuant to requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management has been approved by the Board of Directors has been prepared according to the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR V. N. PUROHIT & CO.
Chartered Accountants
Firm Regn. 304040E

Om Prakash Digitally signed by
Om Prakash Pareek
Date: 2024.02.14
12:20:42 +05'30'
Pareek

O. P. Pareek
Partner
Membership No. 014238
UDIN: 24014238BKAUAJ7968

New Delhi, the 14th day of February, 2024